Bristol Stock Analysis

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

USD 57.89  0.14  0.24%

Is it time to bring in Bristol Myers? Bristol Myers Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The small decline in market price for the last few months could raise concerns from investors as the firm closed today at a share price of 57.28 on 8,786,100 in volume. The company executives did not add much value to Bristol Myers investors in June. However, diversifying your holdings with Bristol Myers Squibb or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 1.44. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. Continue to Trending Equities.

Search Stock Analysis

 
Refresh
The Bristol Myers Stock analysis interface makes it easy to digest most current publicly released information about Bristol Myers as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. Bristol stock analysis module also helps to analyze Bristol Myers price relationship with some important fundamental indicators such as market cap and management efficiency.

Bristol Stock Analysis Notes

About 79.0% of the company shares are held by institutions such as insurance companies. The book value of Bristol Myers was currently reported as 22.06. The company has Price/Earnings To Growth (PEG) ratio of 0.44. Bristol Myers Squibb had 1000000:951777 split on the 7th of August 2001. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people. For more info on BRISTOL MYERS SQI please contact Giovanni Caforio at 212 546-4020 or go to www.bms.com.

  Bristol Myers Quarterly Cost of Revenue

Bristol Myers Squibb Investment Alerts

Bristol Myers Squibb generates negative expected return over the last 30 days
Over 79.0% of the company shares are held by institutions such as insurance companies
On 2nd of July 2020 Bristol Myers paid $ 0.45 per share dividend to its current shareholders
Latest headline from simplywall.st: Heres Why Bristol-Myers Squibbs Statutory Earnings Are Arguably Too Conservative - Simply Wall St

Bristol Myers Squibb Upcoming and Recent Events

Upcoming Quarterly Report6th of August 2020
Next Earnings Report29th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End4th of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Bristol Myers Earnings Estimate

EPSEstimate Date
Quarterly Estimate1.436th of August 2020
The above chart is showing Bristol Myers Squibb normalized analysts earnings estimates for actual as well as future EPS values taken as an average expert opinion over the last few years and projected forward

Bristol Myers SEC Filings

Financial Statements and Exhibits. Other Events
View
Financial Statements and Exhibits. Other Events
View
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
Financial Statements and Exhibits. Other Events
View
Financial Statements and Exhibits. Other Events
View
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
Other Events
View
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Bristol Myers Thematic Classifications

Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French
Drugs IdeaDrugs
Drug manufacturing and delivery
Compulsion IdeaCompulsion
Addiction driven consumer products and services

Market Capitalization

The company currently falls under 'Mega-Cap' category with total capitalization of 131.48 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bristol Myers's market, we take the total number of its shares issued and multiply it by Bristol Myers's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Profitablity

The company has Net Profit Margin of 3.08 %, which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is considered to be average in the sector. In the same way, it shows Net Operating Margin of 37.35 %, which entails that for every 100 dollars of revenue, it generated 0.37 of operating income.

Management Efficiency

The entity has Return on Asset of 5.82 % which means that on every $100 spent on asset, it made $5.82 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 3.0 %, implying that it generated $3.0 on every 100 dollars invested. Bristol Myers management efficiency ratios could be used to measure of how well bristol myers squibb is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Return on Investment is likely to grow to 15.40 in 2020. Return on Average Assets is likely to grow to 0.07 in 2020Bristol Myers Total Assets are fairly stable at the moment as compared to the past year. Bristol Myers reported Total Assets of 129.94 Billion in 2019. Assets Non Current is likely to grow to about 108.5 B in 2020, whereas Current Assets are likely to drop slightly above 24.5 B in 2020. Bristol Myers Total Liabilities is fairly stable at the moment as compared to the past year. Bristol Myers reported Total Liabilities of 78.25 Billion in 2019. Liabilities Non Current is likely to grow to about 64.7 B in 2020, whereas Current Liabilities is likely to drop slightly above 15.2 B in 2020.

Technical Drivers

As of the 15th of July 2020, Bristol Myers shows the mean deviation of 1.05, and risk adjusted performance of (0.023406). Bristol Myers Squibb technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Bristol Myers Squibb, which can be compared to its rivals. Please confirm Bristol Myers Squibb semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if Bristol Myers Squibb is priced correctly, providing market reflects its regular price of 57.89 per share. Given that Bristol Myers has jensen alpha of (0.1), we suggest you to validate Bristol Myers Squibb's prevailing market performance to make sure the company can sustain itself at a future point.

Bristol Myers Squibb Price Movement Analysis

The output start index for this execution was twenty with a total number of output elements of fourty-one. The Exponential Moving Average is calculated by weighting recent values of Bristol Myers Squibb more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Bristol Myers Squibb Insider Trading Activities

Bristol Myers Outstanding Bonds

MaturityCouponRating
110122AA6 7.15%06/15/20237.15
A+
110122AB4 6.8%11/15/20266.8
A+
110122AC2 6.875%08/01/20976.875
A+
110122AP3 5.875%11/15/20365.875
A+
110122AQ1 6.125%05/01/20386.125
A+
110122AS7 0.875%08/01/20170.875
A+
110122AT5 2.0%08/01/20222.0
A+
110122AU2 3.25%08/01/20423.25
A+

Bristol Myers Predictive Indicators

Bristol Myers Forecast Models

About Bristol Myers Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bristol Myers stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bristol shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Bristol Myers. By using and applying Bristol Stock analysis, traders can create a robust methodology for identifying Bristol entry and exit points for their positions.
Last ReportedProjected for 2020
Operating Margin 22.62  23.88 
EBITDA Margin 0.26  0.25 
Gross Margin 0.69  0.67 
Profit Margin 0.13  0.14 
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people.

Current Bristol Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bristol analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bristol analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
65.78Buy9Odds
Bristol Myers Squibb current and past analyst recommendations published by a number of research institutions as well as average analyst consensus. Most Bristol analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bristol stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bristol Myers Squibb, talking to its executives and customers, or listening to Bristol conference calls.
Bristol Analyst Advice Details

Bristol Stock Analysis Indicators

Quick Ratio1.38
Fifty Two Week Low42.48
Trailing Annual Dividend Rate1.72
Revenue Growth82.10%
Payout Ratio273.02%
Shares Short Prior Month34.43M
Average Daily Volume Last 10 Day11.02M
Average Daily Volume In Three Month15.81M
Shares Percent Shares Out1.35%
Gross Margins75.38%
Short Percent Of Float1.35%
Forward Price Earnings7.83
Float Shares2.26B
Fifty Two Week High68.34
Enterprise Value To Ebitda14.17
Fifty Day Average59.08
Two Hundred Day Average60.58
Trailing Annual Dividend Yield2.89%
Enterprise Value To Revenue5.29
Continue to Trending Equities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page